Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

NCT01376245 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus

NCT01856621 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

NCT01342913 ·Status: COMPLETED ·Phase: PHASE3

Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product

NCT00291382 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110 ·Status: COMPLETED ·Phase: PHASE3

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01381471 ·Status: COMPLETED

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler

NCT04147572 ·Status: COMPLETED ·Phase: NA

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

NCT00468975 ·Status: COMPLETED ·Phase: PHASE2

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

NCT00830102 ·Status: COMPLETED ·Phase: PHASE2

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)

NCT01978145 ·Status: COMPLETED ·Phase: PHASE3

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma

NCT01978119 ·Status: COMPLETED ·Phase: PHASE3

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients

NCT01657487 ·Status: UNKNOWN ·Phase: PHASE4

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

NCT02477397 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50

NCT03562923 ·Status: UNKNOWN ·Phase: PHASE3

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

NCT00774761 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621 ·Status: COMPLETED ·Phase: PHASE3

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01168310 ·Status: COMPLETED ·Phase: PHASE2

Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease

NCT00268177 ·Status: COMPLETED ·Phase: PHASE3

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

NCT00975195 ·Status: COMPLETED ·Phase: PHASE4

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

NCT00527826 ·Status: COMPLETED ·Phase: PHASE4

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT01551758 ·Status: COMPLETED ·Phase: PHASE3

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01053988 ·Status: COMPLETED ·Phase: PHASE3

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01131806 ·Status: UNKNOWN ·Phase: PHASE4

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230 ·Status: COMPLETED ·Phase: PHASE3

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634 ·Status: COMPLETED ·Phase: PHASE4